Biggest News Aggregation in the World
📰 About Sickle News

About Sickle News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from About Sickle. Real-time updates on events, politics, business and more.

Global Blood Therapeutics, Inc.: MHRA Grants Marketing Authorization for GBT's Oxbryta (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

Voxelotor is the first medicine approved in Great Britain to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cause of sickle cell diseaseSOUTH SAN FRANCISCO, Calif., July
United States United Kingdom Great Britain Informationfor Oxbryta Steven Immergut Courtney Roberts

Global Blood Therapeutics, Inc.: Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT's Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease

LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics (GBT) today announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has awarded a positive scientific opinion
Ministry Of Health United Arab Emirates United States United Kingdom City Of Great Britain

Investegate |Global Blood Therapeutics, Inc Announcements | Global Blood Therapeutics, Inc: Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT's Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease

Investegate announcements from Global Blood Therapeutics, Inc, Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT’s Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease
Ministry Of Health United Arab Emirates United States United Kingdom City Of Great Britain

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science